AstraZeneca Fourth Quarter and Full-Year 2011 Results - Interviews

LONDON, February 2, 2012 /PRNewswire/ --

AstraZeneca, the Anglo-Swedish pharmaceutical company, said that government price intervention had reduced its revenues by about $1bn as it announced further restructuring alongside its full-year results.

In an interview on http://www.cantos.com, David Brennan, CEO, discusses AstraZeneca's portfolio performance including Brilinta and Crestor, and the prospects for the  pipeline in light of recent disappointments.

He also reaffirms his strong commitment to returning cash to shareholders. 

Also interviewed about the rationale behind the latest phase of the restructuring, Martin Mackay, President, R&D, said:

"We have to be a very flexible organisation to make sure that we're dynamic enough to work in the environment that we work in but also produce great medicines."

Tony Zook, EVP, Global Commercial, also talks about his confidence in AstraZeneca's ability to deliver top line performance and the importance of emerging markets for future growth. 

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-207-936-1352.


SOURCE AstraZeneca

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.